Common Contracts
8 similar Employment Agreement contracts by Oncogenex Pharmaceuticals, Inc., Achieve Life Sciences, Inc.
Amended and Restated Employment AgreementEmployment Agreement • March 16th, 2023 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Cindy Jacobs (the “Executive”) and Achieve Life Sciences, Inc., a Washington corporation (the “Employer” or the “Company”) as of September 27, 2022 (the “Effective Date”). This Agreement supersedes the Executive’s Amended and Restated Employment Agreement, dated September 28, 2020, the Executive’s Employment Agreement with OncoGenex, Inc., dated November 3, 2009, the Executive’s Amended and Restated Employment Agreement with OncoGenex, Inc., dated September 12, 2005, the Employee Retention Agreement with OncoGenex Technologies Inc., a Canadian Corporation, dated October 23, 2007, and any other prior employment-related agreements (the “Prior Agreements”).
Amended and Restated Employment AgreementEmployment Agreement • November 12th, 2020 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances • Washington
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between John Bencich (the “Executive”) and Achieve Life Sciences, Inc., a Washington corporation (the “Employer” or the “Company”) as of September 28, 2020 (the “Effective Date”). This Agreement supersedes the Executive’s Employment Agreements with the Employer, dated September 22, 2016 and August 11, 2014 (together, the “Prior Agreements”).
Amended and Restated Employment AgreementEmployment Agreement • November 12th, 2020 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances • Washington
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Cindy Jacobs (the “Executive”) and Achieve Life Sciences, Inc., a Washington corporation (the “Employer” or the “Company”) as of September 28, 2020 (the “Effective Date”). This Agreement supersedes the Executive’s Employment Agreement with OncoGenex, Inc., dated November 3, 2009, the Executive’s Amended and Restated Employment Agreement with OncoGenex, Inc., dated September 12, 2005, the Employee Retention Agreement with OncoGenex Technologies Inc., a Canadian Corporation, dated October 23, 2007, and any other prior employment-related agreements (the “Prior Agreements”).
Employment AgreementEmployment Agreement • November 10th, 2016 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Washington
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between John Bencich (the “Executive”) and OncoGenex Pharmaceuticals, Inc., a Washington corporation (the “Employer” or the “Company”) as of September 22, 2016 (the “Effective Date”). This Agreement supersedes the Executive’s Employment Agreement with the Employer, dated August 11, 2014 (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 7th, 2014 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Washington
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between John Bencich (the “Executive”) and OncoGenex Pharmaceuticals, Inc., a Washington corporation (the “Employer” or the “Company”) as of August 11, 2014 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 4th, 2013 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Washington
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Susan Wyrick (the “Executive”) and OncoGenex Pharmaceuticals, Inc., a Washington corporation (the “Employer” or the “Company”) as of February 1, 2013 (the “Effective Date”). This Agreement supercedes the Executive’s prior employment-related agreements (the “Prior Agreements”).
Employment AgreementEmployment Agreement • November 8th, 2010 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Washington
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Michelle Burris (the “Executive”) and OncoGenex Pharmaceuticals, Inc., a Washington corporation (the “Employer” or the “Company”) on November 5, 2010 and is effective as of January 3, 2011 (the “Effective Date”).
Employment AgreementEmployment Agreement • November 5th, 2009 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Washington
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Cindy Jacobs (the “Executive”) and OncoGenex Pharmaceuticals, Inc., a Washington corporation (the “Employer” or the “Company”) as of November 3, 2009 (the “Effective Date”). This Agreement supercedes the Executive’s Amended and Restated Employment Agreement with OncoGenex, Inc., dated September 12, 2005, the Employee Retention Agreement with OncoGenex Technologies Inc., a Canadian Corporation, dated October 23, 2007, and any other prior employment-related agreements (the “Prior Agreements”).
